PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor...

Area of Science:

• Cardiovascular Biology
• Molecular Biology
• Cell Cycle Regulation

Background:

• Vascular smooth muscle cell (SMC) proliferation is a key factor in occlusive cardiovascular diseases.
• The nuclear receptor PPARalpha regulates lipid metabolism and inflammation, but its role in SMC growth is unclear.

Purpose of the Study:

• To investigate the role of PPARalpha in regulating vascular SMC proliferation.
• To elucidate the molecular mechanisms by which PPARalpha influences SMC cell-cycle progression.

Main Methods:

• Analysis of PPARalpha's effect on SMC cell-cycle progression at the G1/S transition.
• Investigation of PPARalpha's transcriptional regulation of the p16INK4a (p16) gene, including promoter binding and transcription factor interactions.
• Utilizing a carotid arterial-injury mouse model to assess the in vivo effects of p16 deficiency and PPARalpha activation on SMC proliferation and intimal hyperplasia.

Main Results:

• PPARalpha inhibits SMC cell-cycle progression by targeting the cyclin-dependent kinase inhibitor p16INK4a, preventing retinoblastoma protein phosphorylation.
• PPARalpha activates p16 gene transcription via direct promoter binding and interaction with Sp1.
• p16 deficiency exacerbates SMC proliferation and intimal hyperplasia in a mouse model.
• PPARalpha activation inhibits in vivo SMC growth, an effect dependent on p16 expression.

Conclusions:

• PPARalpha inhibits vascular SMC proliferation through the induction of p16INK4a.
• The identified PPARalpha/p16 pathway represents a novel mechanism for controlling SMC cell-cycle progression.
• This pathway holds potential as a pharmacological target for preventing cardiovascular occlusive complications associated with atherosclerosis.